Immune Design Corp. (NASDAQ: IMDZ), an immunological design company, was founded in 2008 and is headquartered in Seattle, Washington, with 55 full-time employees. It is a clinical stage immunotherapy company engaged in the research and development of in vivo cancer treatments.
Immune Design Corp. (IMDZ):
Immune Design is a clinical-stage immunotherapy company that adopts a new generation of in vivo methods to fight the body’s immune system against diseases. It is mainly based on its ZVex and GLAAS discovery platforms to develop oncology candidate products and create tumor-specific cytotoxicity. T cells (CTL) to fight cancer.
Immune Design’s main product candidates include:
- CMB305, a cancer vaccine against the NY-ESO-1 tumor antigen, is undergoing phase II trials as a monotherapy for patients with synovial and MRCL sarcoma;
- G100, using a unique immuno-oncology method, this method can solve the shortcomings of existing therapies, and it is possible to treat a wide range of patient groups. G100 is an antigen-agnostic intratumor product candidate, used as monotherapy and combination therapy to treat patients with follicular non-Hodgkin’s lymphoma;
- The company is also developing CA21, a multi-targeting enhancer used to treat a variety of solid tumors;
- ZVex-IL12 is used to treat TBD tumors.
- In addition, its technology is also used in the field of infectious diseases and allergic diseases.
Immune Design Corporation and California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC and Sanofi (Sanofi) signed a license agreement; and signed a cooperation agreement with Sanofi Pasteur.